Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
Condition: Liver Cirrhosis, Biliary Interventions: Drug: Obeticholic acid; Drug: Bezafibrate 200 MG; Drug: OCA Placebo; Drug: Bezafibrate 200 mg Placebo; Drug: Bezafibrate 400 MG; Drug: Bezafibrate 400 mg Placebo Sponsor: Intercept Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials